Clinical trials: sponsored by Bayer
Venous Thromboembolism
Dose-confirmatory Bridging Study in Total Hip Replacement
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing…
- Trial name
- NCT01205932
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 41 sites in Japan
- Volunteers
- 402 people
- Sponsor
- Bayer
Venous Thromboembolism
Xarelto Regulatory Post-Marketing Surveillance
This study is to identify the following problems and questions with respect to the safety and effectiveness of Xarelto in comparison with other pharmacologic agents in the prophylaxis of venous thromboembolism (VTE) in a large…
- Trial name
- NCT01029743
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)
- Where
- South Korea
- Volunteers
- 3,388 people
- Sponsor
- Bayer
Pulmonary Embolism
Venous Thromboembolism (VTE) Treatment Study in Japanese Pulmonary Embolism (PE) Patients
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of rivaroxaban in the treatment of pulmonary embolism (PE) and the prevention of the occurrence and the recurrence…
- Trial name
- NCT01516814
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Unfractionated heparin, Warfarin
- Where
- 31 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Bayer
Stroke, Embolism
Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients
This is local prospective multicenter observational non-interventional local study. Primary study objective is investigate and describe prescription pattern of neurologists in secondary stroke or non-CNS (non-Central Nervous…
- Trial name
- NEURO-XAR (NCT01925755)
- Testing
- Rivaroxaban ( Xarelto, BAY59-7939)
- Where
- Russia
- Volunteers
- 209 people
- Sponsor
- Bayer
Atrial Fibrillation
BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies
According to recent guidelines, long-term anticoagulation is recommended for patients with atrial fibrillation (AF) and a risk profile with CHA2DS2-VASc score of 1 or more.
- Trial name
- NCT02090543
- Testing
- Phenprocoumon (Marcumar), Rivaroxaban (Xarelto, BAY-59 7939)
- Where
- Germany
- Volunteers
- 647 people
- Sponsor
- Bayer
Venous Thrombosis
Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication
National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues in deep venous…
- Trial name
- SATORI (NCT01805544)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- France
- Volunteers
- 113 people
- Sponsor
- Bayer
Venous Thromboembolism
Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty
The main goal is to provide additional information to the risk-benefit assessment of the drug.
- Trial name
- XAMOS (NCT00831714)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard care treatment for VTE prophylaxis
- Where
- 42 sites in Australia, Austria and 40 more
- Volunteers
- 19,076 people
- Sponsor
- Bayer
Deep Vein Thrombosis, Venous Thrombosis
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for…
- Trial name
- XALIA (NCT01619007)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care
- Where
- 21 sites in Austria, Belgium and 19 more
- Volunteers
- 5,145 people
- Sponsor
- Bayer
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE)
This is a local, prospective, multicenter, non-interventional, observational study. Primary objective is to describe how in "real life" thromboprophylaxis is carried out after the discharge from a hospital in the patients who…
- Trial name
- SOPRANO (NCT01444586)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Russia
- Volunteers
- 2,293 people
- Sponsor
- Bayer
Atrial Fibrillation
Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism
The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with non-valvular AF treated with Xarelto…
- Trial name
- BOX-AF (NCT01855139)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Belgium
- Volunteers
- 106 people
- Sponsor
- Bayer
Atrial Fibrillation
Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication
National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues for stroke prevention…
- Trial name
- SAFARI (NCT01805531)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- France
- Volunteers
- 411 people
- Sponsor
- Bayer
Venous Thromboembolism
Dose-confirmatory Bridging Study in Total Knee Replacement
The objective of this dose-confirmatory bridging study is to investigate the safety and efficacy of rivaroxaban 5 to 10 mg once-daily (od) dosing in the prevention of venous thromboembolism (VTE) in Japanese patients undergoing…
- Trial name
- NCT01206972
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 33 sites in Japan
- Volunteers
- 302 people
- Sponsor
- Bayer
Deep Vein Thrombosis
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of two different dosages of rivaroxaban in the treatment of deep vein thrombosis (DVT) and the prevention of the…
- Trial name
- NCT01516840
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Unfractionated heparin, Warfarin
- Where
- 29 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Bayer
Venous Thrombosis
Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)
The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients with acute deep vein thrombosis treated…
- Trial name
- BOX-DVT (NCT01855100)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Belgium
- Volunteers
- 131 people
- Sponsor
- Bayer
Neoplasms
Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Clinical study to determine safety, tolerability, to measure how the drug is metabolized by the body and to determine the maximum tolerated dose of BAY1000394 given in an intermittent 3 days on / 4 days off schedule to patients…
- Trial name
- NCT01188252
- Testing
- Roniciclib (BAY1000394)
- Where
- 9 sites in United States, France and 1 more
- Volunteers
- 112 people
- Sponsor
- Bayer
Bone Metastases, Castration-Resistant Prostate Cancer
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
The main purpose of this study is to establish a recommended dose of Alpharadin to be used in combination with docetaxel in patients with bone metastases from castration-resistant prostate cancer and to investigate safety and…
- Trial name
- NCT01106352
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Docetaxel
- Where
- 7 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Bayer
Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of a single oral dose of BAY63-2521 in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00640315
- Testing
- Riociguat (Adempas, BAY63-2521) 1.0 mg, Riociguat (Adempas, BAY63-2521) 2.5 mg
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Bayer
Neoplasms
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
This is the first study where BAY1125976 is given to humans. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated…
- Trial name
- NCT01915576
- Testing
- BAY1125976
- Where
- 7 sites in United States, France and 2 more
- Volunteers
- 79 people
- Sponsor
- Bayer
Hysterectomy
Proportion of Hysterectomy After Female Sterilization
The objective of this study is to describe the proportion of hysterectomy in patients that had undergone sterilization through hysteroscopic device placement and the patients that had undergone sterilization through tubal…
- Trial name
- NCT02532361
- Testing
- Hysteroscopic device placement including Essure (ESS305, BAY1454032), Tubal ligation
- Where
- United States
- Volunteers
- 10,578 people
- Sponsor
- Bayer
Neoplasms, Bone Diseases
Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions
This phase Ib combination study is being conducted to assess the safety and tolerability of radium Ra 223 dichloride in combination with paclitaxel in cancer subjects with bone lesions with special focus on Grade 3/4 incidence of…
- Trial name
- NCT02442063
- Testing
- Radium Ra 223 dichloride (Xofigo, BAY88-8223), paclitaxel
- Where
- 5 sites in Finland, Israel and 1 more
- Volunteers
- 15 people
- Sponsor
- Bayer